Remedy Robotics raises $62M Series B to push N1 toward FDA
TL;DR
- Remedy Robotics closed a $62 million Series B led by DCVC, with UC Investments, Skip Capital and Hostplus joining as new investors.
- The company plans a pivotal clinical trial with the University of California network and targets FDA approval for neurovascular intervention.
- Remedy says it completed the world's first remote neurointerventional procedures using its N1 System in October 2025.
Remedy Robotics, a San Francisco healthcare and physical-AI company, has closed a $62 million Series B led by DCVC to push its N1 endovascular robot toward FDA approval for neurovascular intervention, according to the company's announcement on PR Newswire. New investors UC Investments, Skip Capital and Hostplus joined the round; existing backers Build Collective by Tony Fadell, Blackbird, Divergent Capital and KdT Ventures doubled down.
The money underwrites a planned pivotal clinical trial with the University of California network and continued deployment of prototype N1 systems across what the company says is more than 100 hospitals worldwide. The N1 is an AI-enabled platform that uses machine learning to analyze preoperative imaging, simulate cases in advance, provide real-time 3D-2D image registration and complete entire endovascular procedures robotically, designed to run on-site, remote, or autonomously across neurovascular, coronary and peripheral vascular care. In October 2025, Remedy said it had successfully completed "the world's first remote neurointerventional procedures using the N1 System."
Dr. David Bell, CEO and co-founder, framed the stakes as an access gap: "Endovascular intervention is the gold standard treatment for stroke and many cardiovascular emergencies, yet access remains limited to a small number of hospitals." CTO and co-founder Jake Sganga said the company is "particularly excited to deepen our partnership with the University of California, having worked closely with their clinical experts since 2021." DCVC's James Hardiman, General Partner, called Remedy "a new generation of medical robotics and physical AI companies."
Healthcare AI has been a thinner slice of our feed than the rest of AI funding, with 82 tracked stories in the last 90 days against 438 for AI funding overall. Remedy's round sits near the top of that healthcare set by dollar size.
Originally reported by prnewswire.com
Read the original article →Original headline: Remedy Robotics Raises $62M Series B Led by DCVC to Push N1 Endovascular Robot Toward FDA